| Schedule of Reconciliation to the Consolidated Net Loss |
A reconciliation to
the consolidated net loss for the three and six months ended June 30, 2025 and 2024 is included at the bottom of the table below.
| |
|
Three Months Ended
June 30, |
|
|
Six Months Ended
June 30, |
|
| Significant segment expenses |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
| General and administrative (1) |
|
|
1,460,723 |
|
|
|
1,300,277 |
|
|
|
3,157,148 |
|
|
|
3,197,996 |
|
| Pre-clinical research (1) |
|
|
103,343 |
|
|
|
796,595 |
|
|
|
165,336 |
|
|
|
1,226,979 |
|
| CMC (1) |
|
|
99,413 |
|
|
|
420,951 |
|
|
|
324,010 |
|
|
|
798,771 |
|
| Clinical development (1) |
|
|
1,928,275 |
|
|
|
1,068,655 |
|
|
|
3,363,079 |
|
|
|
1,894,772 |
|
| Depreciation and amortization |
|
|
161,746 |
|
|
|
162,257 |
|
|
|
323,454 |
|
|
|
324,514 |
|
| Share based compensation expense |
|
|
57,645 |
|
|
|
160,952 |
|
|
|
156,203 |
|
|
|
507,429 |
|
| Other segment items (2) |
|
|
(246 |
) |
|
|
35,347 |
|
|
|
1,848 |
|
|
|
35,347 |
|
| Total operating and segment expenses |
|
|
3,810,899 |
|
|
|
3,945,034 |
|
|
|
7,491,078 |
|
|
|
7,985,808 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Reconciliation of net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Change in fair value of warrant liabilities |
|
|
(8,436 |
) |
|
|
(35,622 |
) |
|
|
68,431 |
|
|
|
(8,906 |
) |
| Realized foreign currency translation loss from dissolution of subsidiaries |
|
|
- |
|
|
|
- |
|
|
|
(7,171 |
) |
|
|
- |
|
| Foreign currency gain/(loss) |
|
|
29,290 |
|
|
|
- |
|
|
|
29,290 |
|
|
|
- |
|
| Other income |
|
|
19,464 |
|
|
|
- |
|
|
|
19,464 |
|
|
|
- |
|
| Interest and dividends, net |
|
|
54,424 |
|
|
|
114,407 |
|
|
|
101,669 |
|
|
|
267,625 |
|
| Segment and consolidated net loss |
|
|
3,716,157 |
|
|
|
3,866,249 |
|
|
|
7,279,395 |
|
|
|
7,727,089 |
|
| (1) | includes personnel costs and excludes share-based compensation expense |
| (2) | includes loss from sale of assets, and loss on asset write offs |
|